Quote:

---

---

Zoom: I don't think either one of your command of English is good enough to understand one another. Yes, Urano is using recombinant MANF for diabetes (to fix eye damage). But for the disease itself he is using gene therapy, which is not our recombinant MANF.
Urano has stated this several times but you don't understand what he is saying. Gene therapy is targeting endogenous MANF production, not using recombinant MANF injections

Quote:

---

---

The License expands the company's extensive intellectual property portfolio for MANF, including composition of matter and method of use patents and patent applications worldwide for MANF and derivative sequences for protein therapy, gene therapy and cell therapy applications.